📣 VC round data is live. Check it out!
- Public Comps
- Mindray
Mindray Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mindray and similar public comparables like ResMed, Alcon, Agilent, GE HealthCare and more.
Mindray Overview
About Mindray
Shenzhen Mindray Bio-Medical Electronics Co Ltd is a developer, manufacturer, and supplier of medical devices. The company is focused on the medical industry in the fields of Patient Monitoring & Life Support, InVitro Diagnostics, and Medical Imaging.
Founded
1999
HQ

Employees
21.7K
Website
Financials (LTM)
EV
$28B
Valuation Multiples
Start free trialMindray Financials
Mindray reported last 12-month revenue of $5B and EBITDA of $2B.
In the same LTM period, Mindray generated $3B in gross profit, $2B in EBITDA, and $1B in net income.
Revenue (LTM)
Mindray P&L
In the most recent fiscal year, Mindray reported revenue of $5B and EBITDA of $2B.
Mindray is profitable as of last fiscal year, with gross margin of 60%, EBITDA margin of 34%, and net margin of 24%.
Financial data powered by Morningstar, Inc.
Mindray Stock Performance
Mindray has current market cap of $30B, and enterprise value of $28B.
Market Cap Evolution
Mindray's stock price is $24.88.
Mindray share price increased by 1.0% in the last 30 days, and decreased by 24.1% in the last year.
Mindray has an EPS (earnings per share) of $0.99.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28B | $30B | -0.8% | 1.0% | -8.8% | -24.1% | $0.99 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMindray Valuation Multiples
Mindray trades at 5.5x EV/Revenue multiple, and 16.8x EV/EBITDA.
EV / Revenue (LTM)
Mindray Financial Valuation Multiples
As of May 12, 2026, Mindray has market cap of $30B and EV of $28B.
Mindray has a P/E ratio of 25.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mindray Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Mindray Margins & Growth Rates
Mindray grew revenue by 7% and EBITDA by 2% in the last fiscal year.
In the most recent fiscal year, Mindray reported gross margin of 60%, EBITDA margin of 34%, and net margin of 24%.
Mindray Margins
Mindray Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Mindray Operational KPIs
Mindray's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Mindray's Rule of 40 is 40% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mindray's Rule of X is 51% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Mindray Competitors
Mindray competitors include ResMed, Alcon, Agilent, GE HealthCare, Fresenius, Medline, Waters, Philips, Halma and DexCom.
Most Mindray public comparables operate across Medical Devices, Medical Supplies, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.7x | 5.2x | 15.1x | 13.5x | |||
| 3.3x | 3.2x | 12.7x | 12.6x | |||
| 4.8x | 4.6x | 16.5x | 15.9x | |||
| 1.8x | 1.7x | 9.6x | 9.8x | |||
| 1.4x | 1.3x | 8.3x | 8.2x | |||
| 1.5x | 1.5x | 12.6x | 12.4x | |||
| 12.3x | 8.9x | 34.4x | 26.4x | |||
| 1.5x | 1.5x | 9.2x | 9.1x | |||
This data is available for Pro users. Sign up to see all Mindray competitors and their valuation data. Start Free Trial | ||||||
Mindray M&A Activity
Mindray has acquired 1 company to date.
Last acquisition by Mindray was on May 17th 2021. Mindray acquired HyTest for $663M (EV/Revenue multiple of ).
Latest Acquisitions by Mindray
| Description | HyTest is a Turku-headquartered supplier of immunoassay reagents in Finland. The company manufactures monoclonal antibodies, antigens, cardiac troponin I, troponin complexes, and biomarkers for diagnostic assay development and research in biotechnology laboratories worldwide. |
| HQ Country | |
| HQ City | Turku |
| Deal Date | 17 May 2021 |
| Valuation | $663M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Mindray acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mindray
| When was Mindray founded? | Mindray was founded in 1999. |
| Where is Mindray headquartered? | Mindray is headquartered in China. |
| How many employees does Mindray have? | As of today, Mindray has over 21K employees. |
| Is Mindray publicly listed? | Yes, Mindray is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Mindray? | Mindray trades under 300760 ticker. |
| When did Mindray go public? | Mindray went public in 2018. |
| Who are competitors of Mindray? | Mindray main competitors include ResMed, Alcon, Agilent, GE HealthCare, Fresenius, Medline, Waters, Philips, Halma, DexCom. |
| What is the current market cap of Mindray? | Mindray's current market cap is $30B. |
| What is the current revenue of Mindray? | Mindray's last 12 months revenue is $5B. |
| What is the current revenue growth of Mindray? | Mindray revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Mindray? | Current revenue multiple of Mindray is 5.5x. |
| Is Mindray profitable? | Yes, Mindray is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mindray? | Mindray's last 12 months EBITDA is $2B. |
| What is Mindray's EBITDA margin? | Mindray's last 12 months EBITDA margin is 33%. |
| What is the current EV/EBITDA multiple of Mindray? | Current EBITDA multiple of Mindray is 16.8x. |
| What is the current FCF of Mindray? | Mindray's last 12 months FCF is $1B. |
| What is Mindray's FCF margin? | Mindray's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of Mindray? | Current FCF multiple of Mindray is 19.9x. |
| How many companies Mindray has acquired to date? | As of May 2026, Mindray has acquired 1 company. |
| What was the largest acquisition by Mindray? | $663M acquisition of HyTest on 17th May 2021 was the largest M&A Mindray has done to date. |
| What companies Mindray acquired? | Mindray acquired HyTest. |
| In how many companies Mindray has invested to date? | Mindray hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Mindray
Lists including Mindray
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
